Trial Profile
A phase III, open-label, extension, multi-center, safety and efficacy study of lisdexamfetamine dimesylate (LDX) in adolescents aged 13-17 with attention deficit/hyperactivity disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jun 2021
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Shire
- 07 Apr 2014 New trial record